News & Events

ACR Convergence 2021

UCLA's Division of Rheumatology was well represented at the 2021 ACR Convergence with 23 posters, 5 abstracts, 3 plenaries, 3 industry sessions, 3 community sessions, 1 review course, and 1 study group. Congratulations to the faculty and fellows who contribute to the presentations this year!

Posters:

• ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis
• Suppressed Paraoxonase-1 Activity and Elevated Oxylipins Associate with the Presence of Small Airways Disease in Patients with Rheumatoid Arthritis
• Economic and Healthcare Resource Use Burden of Systemic Sclerosis
• Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
• Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
• Decreased HDL Levels and Antioxidant Function in Juvenile Dermatomyositis
• Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
• Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis
• Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
• Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
• Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
• Paraoxonase-1: Potential Novel Marker of Disease Extent and Activity in Systemic Sclerosis
• Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment
• NLP-Based Clustering Methods Can Efficiently Categorize Scientific Abstracts for Medical Conferences
• “What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
• Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis
• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
• Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
• Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
• Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
• Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
• Clinical Characteristics and Reliability of a Self-Reported Diagnosis of Large-Vessel Vasculitis
• Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

Plenaries:

• Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
• Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
• Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features

Oral Abstract Sessions: 

• Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
• Relationship Between Paraoxonase-1 Genotype, Activity, and Malignancies in Patients with RA Receiving Tofacitinib
• Trends in Adverse Pregnancy Outcomes Among Women with Systemic Sclerosis in the United States
• Clinical Heterogeneity of the VEXAS Syndrome: A Case Series
• The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

Review Courses:

• Impact of Rheumatic Disease Management on Cardiovascular Risk

Study Groups:

• Humanities in Medicine – Rheum for More Insight

Industry Sessions:

• SAPHNELO™ (anifrolumab-fnia): The First-in Class Type 1 Interferon (IFN-1) Signaling Inhibitor
• Treatment Priorities in Systemic Lupus Erythematosus: Focus on Musculoskeletal Symptoms and Patient-Reported Outcomes
• Woman Leaders in Rheumatology: Leadership in a Virtual World

Community Hub Sessions:

• CH Ultrasound: The Business of MSUS
• CH SLE: Meet the Masters: Reflections on Lupus in 2021?
• CH Leadership: Cocktail Hour: Creating the Ideal Work / Life Balance?

Return to Rheumatology Homepage